Register a trial

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05081557




Registration number
NCT05081557
Ethics application status
Date submitted
7/10/2021
Date registered
18/10/2021

Titles & IDs
Public title
A Study to Assess Real-World Use, Safety, and Effectiveness of Oral Upadacitinib in Adult and Adolescent (>=12 Years Old) Participants With Atopic Dermatitis
Scientific title
Real World Utilization of Upadacitinib in Adult and Adolescent Patients Living With Moderate to Severe Atopic Dermatitis (AD-VISE)
Secondary ID [1] 0 0
P20-441
Universal Trial Number (UTN)
Trial acronym
AD-VISE
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Atopic Dermatitis 0 0
Condition category
Condition code
Skin 0 0 0 0
Dermatological conditions
Skin 0 0 0 0
Other skin conditions
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders

Intervention/exposure
Study type
Observational
Patient registry
Target follow-up duration
Target follow-up type
Description of intervention(s) / exposure
Participants Receiving Upadacitinib - Participants receiving upadacitinib for atopic dermatitis.
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Upadacitinib (UPA) Utilization Patterns
Timepoint [1] 0 0
Up to Approximately 24 Months
Primary outcome [2] 0 0
Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) 0/1
Timepoint [2] 0 0
Month 4
Primary outcome [3] 0 0
vIGA-AD 0/1 Among Participants Who Achieved vIGA-AD 0/1 at Month 4
Timepoint [3] 0 0
Month 24
Secondary outcome [1] 0 0
Modification of UPA or Concomitant AD Therapy and Associated Timing, Reasons
Timepoint [1] 0 0
Month 24
Secondary outcome [2] 0 0
Percentage of Participants Achieving Eczema Area and Severity Index (EASI) 75
Timepoint [2] 0 0
Up to Approximately 24 months
Secondary outcome [3] 0 0
Percentage of Participants Achieving EASI 90
Timepoint [3] 0 0
Up to Approximately 24 Months
Secondary outcome [4] 0 0
Percentage of Participants Achieving EASI 100
Timepoint [4] 0 0
Up to Approximately 24 Months
Secondary outcome [5] 0 0
Percentage of Participants Achieving EASI <=1
Timepoint [5] 0 0
Up to Approximately 24 Months
Secondary outcome [6] 0 0
Percentage of Participants Achieving EASI <=5.9
Timepoint [6] 0 0
Up to Approximately 24 Months
Secondary outcome [7] 0 0
Percentage of Participants Achieving EASI <=7
Timepoint [7] 0 0
Up to Approximately 24 Months
Secondary outcome [8] 0 0
Percentage of Participants Achieving vIGA-AD 0/1
Timepoint [8] 0 0
Up to Approximately 24 Months (Excluding Month 4 - Primary Outcome)
Secondary outcome [9] 0 0
Percentage of Participants Achieving Worst Pruritus Numerical Rating Scale (WP-NRS) 0/1
Timepoint [9] 0 0
Up to Approximately 24 Months
Secondary outcome [10] 0 0
Percentage of Participants Achieving WP-NRS <=3
Timepoint [10] 0 0
Up to Approximately 24 Months
Secondary outcome [11] 0 0
Percentage of Participants Achieving WP-NRS reduction >=4
Timepoint [11] 0 0
Up to Approximately 24 Months
Secondary outcome [12] 0 0
Percentage of Participants Achieving Patient Oriented Eczema Measurement (POEM) Score <=2
Timepoint [12] 0 0
Up to Approximately 24 Months
Secondary outcome [13] 0 0
Percentage of Participants Achieving POEM <=7
Timepoint [13] 0 0
Up to Approximately 24 Months
Secondary outcome [14] 0 0
Percentage of Participants Achieving POEM Reduction >=4
Timepoint [14] 0 0
Up to Approximately 24 Months
Secondary outcome [15] 0 0
Percentage of Participants Achieving Dermatology Life Quality Index (DLQI) Score of 0/1
Timepoint [15] 0 0
Up to Approximately 24 Months
Secondary outcome [16] 0 0
Percentage of Participants Achieving DLQI Score <=5
Timepoint [16] 0 0
Up to Approximately 24 Months
Secondary outcome [17] 0 0
Percentage of Participants Achieving DLQI reduction >=4
Timepoint [17] 0 0
Up to Approximately 24 Months
Secondary outcome [18] 0 0
Percentage of Participants Achieving Atopic Dermatitis Control Tool (ADCT) <7 (control)
Timepoint [18] 0 0
Up to Approximately 24 Months
Secondary outcome [19] 0 0
Percentage of Participants Achieving ADCT reduction >=5
Timepoint [19] 0 0
Up to approximately 24 Months
Secondary outcome [20] 0 0
Percentage of Participants who are "Extremely Satisfied" or "Very Satisfied" with their AD Treatment using the Patient Global Impression of Treatment for Atopic Dermatitis (PGIT-AD)
Timepoint [20] 0 0
Up to Approximately 24 Months
Secondary outcome [21] 0 0
Percentage of Participants Remaining on Upadacitinib Once Daily
Timepoint [21] 0 0
Up to Approximately 24 Months
Secondary outcome [22] 0 0
Percentage of Participants Achieving EASI 75 Among Participants Who Achieved EASI 75 at Month 4
Timepoint [22] 0 0
Up to Approximately 24 months
Secondary outcome [23] 0 0
Percentage of Participants Achieving EASI 90 Among Participants Who Achieved EASI 90 at Month 4
Timepoint [23] 0 0
Up to Approximately 24 months
Secondary outcome [24] 0 0
Percentage of Participants Achieving EASI 100 Among Participants Who Achieved EASI 100 at Month 4
Timepoint [24] 0 0
Up to Approximately 24 months
Secondary outcome [25] 0 0
Percentage of Participants Achieving vIGA-AD 0/1 Among Participants Who Achieved vIGA-AD at Month 4
Timepoint [25] 0 0
Up to Approximately 24 Months (Excluding Month 24 - Primary Outcome)
Secondary outcome [26] 0 0
Percentage of Participants Achieving WP-NRS 0/1 Among Participants Who Achieved WP-NRS 0/1 at Month 4
Timepoint [26] 0 0
Up to Approximately 24 Months
Secondary outcome [27] 0 0
Percentage of Participants Achieving DLQI Score of 0/1 Among Participants Achieving DLQI Score of 0/1 at Month 4
Timepoint [27] 0 0
Up to Approximately 24 Months
Secondary outcome [28] 0 0
Percentage of Participants Achieving ADCT Reduction <7 Among Participants Who Achieved ADCT Reduction <7 at Month 4
Timepoint [28] 0 0
Up to approximately 24 Months
Secondary outcome [29] 0 0
Absolute Score and Change from Baseline in EASI
Timepoint [29] 0 0
Up to Approximately 24 months
Secondary outcome [30] 0 0
Absolute Score and Change from Baseline in vIGA-AD
Timepoint [30] 0 0
Up to Approximately 24 months
Secondary outcome [31] 0 0
Absolute Score and Change from Baseline in Body Surface Area (BSA)
Timepoint [31] 0 0
Up to Approximately 24 Months
Secondary outcome [32] 0 0
Absolute Score and Change from Baseline in WP-NRS
Timepoint [32] 0 0
Up to Approximately 24 Months
Secondary outcome [33] 0 0
Absolute Score and Change from Baseline in POEM
Timepoint [33] 0 0
Up to Approximately 24 Months
Secondary outcome [34] 0 0
Absolute Score and Change from Baseline in DLQI
Timepoint [34] 0 0
Up to Approximately 24 Months
Secondary outcome [35] 0 0
Absolute Score and Change from Baseline in ADCT
Timepoint [35] 0 0
Up to Approximately 24 months
Secondary outcome [36] 0 0
Absolute Score and Change from Baseline in PGIT-AD
Timepoint [36] 0 0
Up to Approximately 24 Months
Secondary outcome [37] 0 0
Change from Baseline in Flare Frequency and Duration
Timepoint [37] 0 0
Up to Approximately 24 Months
Secondary outcome [38] 0 0
Change from Baseline in the Number of AD-Related Physician Office or Hospital Visits
Timepoint [38] 0 0
Up to Approximately 24 Months
Secondary outcome [39] 0 0
Absolute Score and Change from Baseline in Work Productivity and Activity Impairment Index for Atopic Dermatitis (WPAI-AD)
Timepoint [39] 0 0
Up to Approximately 24 Months
Secondary outcome [40] 0 0
Time to Achieve EASI 75
Timepoint [40] 0 0
Up to Approximately 24 months
Secondary outcome [41] 0 0
Time to Achieve EASI 90
Timepoint [41] 0 0
Up to Approximately 24 months
Secondary outcome [42] 0 0
Time to Achieve EASI 100
Timepoint [42] 0 0
Up to Approximately 24 months
Secondary outcome [43] 0 0
Time to Achieve vIGA-AD 0/1
Timepoint [43] 0 0
Up to Approximately 24 Months
Secondary outcome [44] 0 0
Time to Achieve WP-NRS 0/1
Timepoint [44] 0 0
Up to Approximately 24 Months
Secondary outcome [45] 0 0
Time to Achieve DLQI Score of 0/1
Timepoint [45] 0 0
Up to Approximately 24 Months
Secondary outcome [46] 0 0
Time to Achieve POEM <=2
Timepoint [46] 0 0
Up to Approximately 24 Months
Secondary outcome [47] 0 0
Time to Achieve ADCT <7
Timepoint [47] 0 0
Up to Approximately 24 Months
Secondary outcome [48] 0 0
Time-Weighted EASI Score
Timepoint [48] 0 0
Up to Approximately 24 Months
Secondary outcome [49] 0 0
Time-Weighted vIGA-AD Score
Timepoint [49] 0 0
Up to Approximately 24 Months
Secondary outcome [50] 0 0
Time-Weighted WP-NRS Score
Timepoint [50] 0 0
Up to Approximately 24 Months
Secondary outcome [51] 0 0
Time-Weighted DLQI Score
Timepoint [51] 0 0
Up to Approximately 24 Months
Secondary outcome [52] 0 0
Percentage of Participants Achieving Treatment Target EASI <8
Timepoint [52] 0 0
Up to Approximately 24 Months
Secondary outcome [53] 0 0
Percentage of Participants Achieving Treatment Target DLQI <=5
Timepoint [53] 0 0
Up to Approximately 24 Months
Secondary outcome [54] 0 0
Percentage of Participants Achieving Treatment Target WP-NRS <=4
Timepoint [54] 0 0
Up to Approximately 24 Months
Secondary outcome [55] 0 0
Percentage of Participants Achieving Combined Treatment Targets of EASI <8, DLQI <=5, and WP-NRS <=4
Timepoint [55] 0 0
Up to Approximately 24 Months

Eligibility
Key inclusion criteria
* Physician confirmed diagnosis of atopic dermatitis (AD) or atopic eczema at baseline.
* Symptom onset >=1-year prior to baseline.
* Initiation of upadacitinib treatment for AD is indicated and prescribed per local label.
* The decision to prescribe UPA is made prior to and independently of study participation.
* Medical and medication history available for previous 6 months.
* Participants who can understand the questionnaires, with parental support as required for adolescents.
* Participants who are able to understand and communicate with the investigator and comply with the requirements of the study.
* Participants who are willing and able to participate in the collection of patient-reported data via cloud-based mobile application using a smart device (i.e., tablet).
* Participants who are willing and able to complete the patient-reported questionnaires.
Minimum age
12 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Participants who are currently participating in interventional research (not including non-interventional study, post-marketing observational study, or registry participation).

Study design
Purpose
Duration
Selection
Timing
Prospective
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
17/11/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
15/10/2026
Actual
Sample size
Target
Accrual to date
Final
873
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC,WA
Recruitment hospital [1] 0 0
Kingsway Dermatology & Aesthetics /ID# 242276 - Miranda
Recruitment hospital [2] 0 0
Veracity Clinical Research /ID# 242275 - Woolloongabba
Recruitment hospital [3] 0 0
Flinders Medical Centre /ID# 242162 - Bedford, Park
Recruitment hospital [4] 0 0
Sinclair Dermatology - Melbourne /ID# 242163 - East Melbourne
Recruitment hospital [5] 0 0
Burswood Dermatology /ID# 243767 - Victoria Park
Recruitment hospital [6] 0 0
Sydney Skin /ID# 242277 - Newtown
Recruitment postcode(s) [1] 0 0
2228 - Miranda
Recruitment postcode(s) [2] 0 0
4102 - Woolloongabba
Recruitment postcode(s) [3] 0 0
5042 - Bedford, Park
Recruitment postcode(s) [4] 0 0
3002 - East Melbourne
Recruitment postcode(s) [5] 0 0
6100 - Victoria Park
Recruitment postcode(s) [6] 0 0
2042 - Newtown
Recruitment outside Australia
Country [1] 0 0
Argentina
State/province [1] 0 0
Buenos Aires
Country [2] 0 0
Argentina
State/province [2] 0 0
Ciudad Autonoma De Buenos Aires
Country [3] 0 0
Argentina
State/province [3] 0 0
Santa Fe
Country [4] 0 0
Argentina
State/province [4] 0 0
Caba
Country [5] 0 0
Austria
State/province [5] 0 0
Oberoesterreich
Country [6] 0 0
Austria
State/province [6] 0 0
Vorarlberg
Country [7] 0 0
Austria
State/province [7] 0 0
Wien
Country [8] 0 0
Canada
State/province [8] 0 0
Alberta
Country [9] 0 0
Canada
State/province [9] 0 0
Manitoba
Country [10] 0 0
Canada
State/province [10] 0 0
New Brunswick
Country [11] 0 0
Canada
State/province [11] 0 0
Newfoundland and Labrador
Country [12] 0 0
Canada
State/province [12] 0 0
Ontario
Country [13] 0 0
Canada
State/province [13] 0 0
Quebec
Country [14] 0 0
Czechia
State/province [14] 0 0
Praha 17
Country [15] 0 0
Czechia
State/province [15] 0 0
Stredocesky Kraj
Country [16] 0 0
Czechia
State/province [16] 0 0
Olomouc
Country [17] 0 0
Czechia
State/province [17] 0 0
Prague
Country [18] 0 0
Czechia
State/province [18] 0 0
Praha
Country [19] 0 0
Greece
State/province [19] 0 0
Achaia
Country [20] 0 0
Greece
State/province [20] 0 0
Attiki
Country [21] 0 0
Greece
State/province [21] 0 0
Evrytania
Country [22] 0 0
Greece
State/province [22] 0 0
Athens
Country [23] 0 0
Greece
State/province [23] 0 0
Larissa
Country [24] 0 0
Hungary
State/province [24] 0 0
Hajdu-Bihar
Country [25] 0 0
Hungary
State/province [25] 0 0
Nograd
Country [26] 0 0
Hungary
State/province [26] 0 0
Vas
Country [27] 0 0
Hungary
State/province [27] 0 0
Budapest
Country [28] 0 0
Hungary
State/province [28] 0 0
Szeged
Country [29] 0 0
Israel
State/province [29] 0 0
H_efa
Country [30] 0 0
Israel
State/province [30] 0 0
HaDarom
Country [31] 0 0
Israel
State/province [31] 0 0
HaMerkaz
Country [32] 0 0
Israel
State/province [32] 0 0
HaTsafon
Country [33] 0 0
Israel
State/province [33] 0 0
Tel-Aviv
Country [34] 0 0
Israel
State/province [34] 0 0
Yerushalayim
Country [35] 0 0
Italy
State/province [35] 0 0
Genova
Country [36] 0 0
Italy
State/province [36] 0 0
Milano
Country [37] 0 0
Italy
State/province [37] 0 0
Piemonte
Country [38] 0 0
Italy
State/province [38] 0 0
Salerno
Country [39] 0 0
Italy
State/province [39] 0 0
Bari
Country [40] 0 0
Italy
State/province [40] 0 0
Catania
Country [41] 0 0
Italy
State/province [41] 0 0
Messina
Country [42] 0 0
Italy
State/province [42] 0 0
Novara
Country [43] 0 0
Italy
State/province [43] 0 0
Roma
Country [44] 0 0
Italy
State/province [44] 0 0
Vicenza
Country [45] 0 0
Mexico
State/province [45] 0 0
Jalisco
Country [46] 0 0
Mexico
State/province [46] 0 0
Nuevo Leon
Country [47] 0 0
Mexico
State/province [47] 0 0
Oaxaca
Country [48] 0 0
Mexico
State/province [48] 0 0
Puebla
Country [49] 0 0
Mexico
State/province [49] 0 0
Yucatan
Country [50] 0 0
Mexico
State/province [50] 0 0
Ciudad de Mexico
Country [51] 0 0
Mexico
State/province [51] 0 0
Mexico City
Country [52] 0 0
Mexico
State/province [52] 0 0
Toluca
Country [53] 0 0
Poland
State/province [53] 0 0
Lodzkie
Country [54] 0 0
Poland
State/province [54] 0 0
Lubelskie
Country [55] 0 0
Poland
State/province [55] 0 0
Malopolskie
Country [56] 0 0
Poland
State/province [56] 0 0
Mazowieckie
Country [57] 0 0
Poland
State/province [57] 0 0
Podkarpackie
Country [58] 0 0
Russian Federation
State/province [58] 0 0
Chelyabinskaya Oblast
Country [59] 0 0
Russian Federation
State/province [59] 0 0
Krasnodarskiy Kray
Country [60] 0 0
Russian Federation
State/province [60] 0 0
Kurskaya Oblast
Country [61] 0 0
Russian Federation
State/province [61] 0 0
Moskva
Country [62] 0 0
Russian Federation
State/province [62] 0 0
Ryazanskaya Oblast
Country [63] 0 0
Russian Federation
State/province [63] 0 0
Stavropol Skiy Kray
Country [64] 0 0
Russian Federation
State/province [64] 0 0
Tatarstan, Respublika
Country [65] 0 0
Spain
State/province [65] 0 0
Barcelona
Country [66] 0 0
Spain
State/province [66] 0 0
La Rioja
Country [67] 0 0
Spain
State/province [67] 0 0
Las Palmas
Country [68] 0 0
Spain
State/province [68] 0 0
Murcia
Country [69] 0 0
Spain
State/province [69] 0 0
Santa Cruz De Tenerife
Country [70] 0 0
Spain
State/province [70] 0 0
Vizcaya
Country [71] 0 0
Spain
State/province [71] 0 0
Granada
Country [72] 0 0
Spain
State/province [72] 0 0
Huelva
Country [73] 0 0
Spain
State/province [73] 0 0
Jaen
Country [74] 0 0
Spain
State/province [74] 0 0
Lugo
Country [75] 0 0
Spain
State/province [75] 0 0
Malaga
Country [76] 0 0
Spain
State/province [76] 0 0
Salamanca
Country [77] 0 0
Spain
State/province [77] 0 0
Santa Cruz de Tenerife
Country [78] 0 0
Spain
State/province [78] 0 0
Sevilla
Country [79] 0 0
Spain
State/province [79] 0 0
Valladolid
Country [80] 0 0
Switzerland
State/province [80] 0 0
Aargau
Country [81] 0 0
Switzerland
State/province [81] 0 0
Nidwalden
Country [82] 0 0
Switzerland
State/province [82] 0 0
Sankt Gallen
Country [83] 0 0
Switzerland
State/province [83] 0 0
Telangana
Country [84] 0 0
Switzerland
State/province [84] 0 0
Ticino
Country [85] 0 0
Switzerland
State/province [85] 0 0
Valais
Country [86] 0 0
Switzerland
State/province [86] 0 0
Zuerich
Country [87] 0 0
Taiwan
State/province [87] 0 0
Keelung
Country [88] 0 0
Taiwan
State/province [88] 0 0
Taipei
Country [89] 0 0
Taiwan
State/province [89] 0 0
Taipei City
Country [90] 0 0
Taiwan
State/province [90] 0 0
Taoyuan City
Country [91] 0 0
United Arab Emirates
State/province [91] 0 0
Abu Dhabi
Country [92] 0 0
United Arab Emirates
State/province [92] 0 0
Dubai

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
AbbVie
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
ABBVIE INC.
Address 0 0
AbbVie
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
ABBVIE CALL CENTER
Address 0 0
Country 0 0
Phone 0 0
844-663-3742
Fax 0 0
Email 0 0
abbvieclinicaltrials@abbvie.com
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Undecided
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results not provided in https://clinicaltrials.gov/study/NCT05081557